DE68922485D1 - Verfahren zur einführung von sauerstoff-17 in gewebe zur bildformung in einem magnetischen resonanzbildformungssystem. - Google Patents

Verfahren zur einführung von sauerstoff-17 in gewebe zur bildformung in einem magnetischen resonanzbildformungssystem.

Info

Publication number
DE68922485D1
DE68922485D1 DE68922485T DE68922485T DE68922485D1 DE 68922485 D1 DE68922485 D1 DE 68922485D1 DE 68922485 T DE68922485 T DE 68922485T DE 68922485 T DE68922485 T DE 68922485T DE 68922485 D1 DE68922485 D1 DE 68922485D1
Authority
DE
Germany
Prior art keywords
imaging
tissue
agent
magnetic resonance
oxygen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68922485T
Other languages
English (en)
Other versions
DE68922485T2 (de
Inventor
Pradeep Gupte
Toshiyuki Arai
Sigmund E Lasker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE68922485D1 publication Critical patent/DE68922485D1/de
Application granted granted Critical
Publication of DE68922485T2 publication Critical patent/DE68922485T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/46—NMR spectroscopy
    • G01R33/465—NMR spectroscopy applied to biological material, e.g. in vitro testing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Physics & Mathematics (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Signal Processing (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
DE68922485T 1988-08-19 1989-08-16 Verfahren zur einführung von sauerstoff-17 in gewebe zur bildformung in einem magnetischen resonanzbildformungssystem. Expired - Lifetime DE68922485T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/234,339 US4996041A (en) 1988-08-19 1988-08-19 Method for introducing oxygen-17 into tissue for imaging in a magnetic resonance imaging system
PCT/US1989/003503 WO1990001953A1 (en) 1988-08-19 1989-08-16 Method for introducing oxygen-17 into tissues for imaging in a magnetic resonance imaging system

Publications (2)

Publication Number Publication Date
DE68922485D1 true DE68922485D1 (de) 1995-06-08
DE68922485T2 DE68922485T2 (de) 1996-01-18

Family

ID=22880951

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68922485T Expired - Lifetime DE68922485T2 (de) 1988-08-19 1989-08-16 Verfahren zur einführung von sauerstoff-17 in gewebe zur bildformung in einem magnetischen resonanzbildformungssystem.

Country Status (9)

Country Link
US (1) US4996041A (de)
EP (1) EP0386199B1 (de)
JP (1) JP2655004B2 (de)
AT (1) ATE121950T1 (de)
AU (1) AU4066589A (de)
CA (1) CA1336165C (de)
DE (1) DE68922485T2 (de)
IL (1) IL91368A (de)
WO (1) WO1990001953A1 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991007990A1 (en) * 1989-11-24 1991-06-13 Toshiyuki Arai Nuclear magnetic resonance agent, detection thereof, and tomography using said agent
US6146657A (en) * 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US5469854A (en) * 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5922304A (en) * 1989-12-22 1999-07-13 Imarx Pharmaceutical Corp. Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5305757A (en) * 1989-12-22 1994-04-26 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US6001335A (en) * 1989-12-22 1999-12-14 Imarx Pharmaceutical Corp. Contrasting agents for ultrasonic imaging and methods for preparing the same
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5352435A (en) * 1989-12-22 1994-10-04 Unger Evan C Ionophore containing liposomes for ultrasound imaging
US20020150539A1 (en) * 1989-12-22 2002-10-17 Unger Evan C. Ultrasound imaging and treatment
US5585112A (en) * 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5705187A (en) * 1989-12-22 1998-01-06 Imarx Pharmaceutical Corp. Compositions of lipids and stabilizing materials
US5656211A (en) * 1989-12-22 1997-08-12 Imarx Pharmaceutical Corp. Apparatus and method for making gas-filled vesicles of optimal size
US5773024A (en) * 1989-12-22 1998-06-30 Imarx Pharmaceutical Corp. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5776429A (en) * 1989-12-22 1998-07-07 Imarx Pharmaceutical Corp. Method of preparing gas-filled microspheres using a lyophilized lipids
US6088613A (en) * 1989-12-22 2000-07-11 Imarx Pharmaceutical Corp. Method of magnetic resonance focused surgical and therapeutic ultrasound
GB9005080D0 (en) * 1990-03-07 1990-05-02 Univ Nottingham Labelled markers
EP0526503B1 (de) * 1990-04-10 1997-06-04 Imarx Pharmaceutical Corp. Polymere und ihre verwendung als kontrastmittel bei der bilderzeugung mit magnetischer resonanz
US5368840A (en) * 1990-04-10 1994-11-29 Imarx Pharmaceutical Corp. Natural polymers as contrast media for magnetic resonance imaging
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US5874062A (en) * 1991-04-05 1999-02-23 Imarx Pharmaceutical Corp. Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents
US5304325A (en) * 1991-11-13 1994-04-19 Hemagen/Pfc Emulsions containing alkyl- or alkylglycerophosphoryl choline surfactants and methods of use
WO1993018796A1 (en) * 1992-03-26 1993-09-30 Toshiyuki Arai Reagent for nuclear magnetic resonance
WO1996003073A1 (en) * 1992-04-14 1996-02-08 Lasker Sigmund E Process for visualizing tissue metabolism using oxygen-17
US5339814A (en) * 1992-04-14 1994-08-23 Lasker Sigmund E Process for visualizing tissue metabolism using oxygen-17
JPH0625014A (ja) * 1992-07-13 1994-02-01 Toshiyuki Arai 核磁気共鳴剤
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5650156A (en) * 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US5362478A (en) * 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US5665382A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US6280383B1 (en) * 1993-03-01 2001-08-28 Fonar Corporation Magnetic resonance imaging
US5433196A (en) * 1993-06-02 1995-07-18 The Board Of Trustees Of The University Of Illinois Oxygen-17 NMR spectroscopy and imaging in the human
US5716597A (en) * 1993-06-04 1998-02-10 Molecular Biosystems, Inc. Emulsions as contrast agents and method of use
IL106066A (en) * 1993-06-18 1997-04-15 British Tech Group Method of measuring the 17o content and distribution in a body
US7083572B2 (en) * 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
US5545396A (en) * 1994-04-08 1996-08-13 The Research Foundation Of State University Of New York Magnetic resonance imaging using hyperpolarized noble gases
US6123919A (en) * 1994-04-08 2000-09-26 The Trustees Of Princeton University Magnetic resonance imaging using hyperpolarized noble gases
US5736121A (en) * 1994-05-23 1998-04-07 Imarx Pharmaceutical Corp. Stabilized homogenous suspensions as computed tomography contrast agents
US6743779B1 (en) 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US5830430A (en) * 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
US6139819A (en) * 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
US6521211B1 (en) * 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
US6033645A (en) * 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent
US6231834B1 (en) 1995-06-07 2001-05-15 Imarx Pharmaceutical Corp. Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
CA2252617A1 (en) 1996-05-01 1997-11-06 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US6414139B1 (en) 1996-09-03 2002-07-02 Imarx Therapeutics, Inc. Silicon amphiphilic compounds and the use thereof
DK1323434T3 (da) * 1996-09-11 2007-11-12 Bristol Myers Squibb Medical I Fremgangsmåde til diagnostisk billeddannelse af nyreregioner under anvendelse af et kontrastmiddel og en vasodilator
US5846517A (en) * 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6143276A (en) * 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US6090800A (en) * 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6537246B1 (en) * 1997-06-18 2003-03-25 Imarx Therapeutics, Inc. Oxygen delivery agents and uses for the same
US20050019266A1 (en) * 1997-05-06 2005-01-27 Unger Evan C. Novel targeted compositions for diagnostic and therapeutic use
US6416740B1 (en) 1997-05-13 2002-07-09 Bristol-Myers Squibb Medical Imaging, Inc. Acoustically active drug delivery systems
US6548047B1 (en) 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
US6123923A (en) * 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
JP2002518651A (ja) * 1998-06-17 2002-06-25 メディ‐フィジクス，インコーポレイテッド 過分極ガス輸送装置及びその輸送方法
US6284222B1 (en) 1998-11-03 2001-09-04 Medi--Physics, Inc. Hyperpolarized helium-3 microbubble gas entrapment methods
WO2000050914A1 (en) 1999-02-23 2000-08-31 Medi-Physics, Inc. Portable system for monitoring the polarization level of a hyperpolarized gas during transport
US6648130B1 (en) * 1999-08-11 2003-11-18 Medi-Physics, Inc. Hyperpolarized gas transport and storage devices and associated transport and storage methods using permanent magnets
CA2401308A1 (en) * 2000-03-13 2001-09-20 Klaus D. Hagspiel Diagnostic procedures using direct injection of gaseous hyperpolarized 129xe and associated systems and products
US7407778B2 (en) * 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders
US7700074B2 (en) * 2002-02-07 2010-04-20 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
US20060257842A1 (en) * 2003-05-29 2006-11-16 Pettegrew Jay W Cryopreservation media and molecules
ATE437884T1 (de) * 2003-05-29 2009-08-15 Jay W Pettegrew Glycerophosphocholin und derivate davon zur medizinischen abbildung von neuropsychiatrischen erkrankungen
CA2560544C (en) 2004-01-16 2015-05-19 Carnegie Mellon University Cellular labeling for nuclear magnetic resonance techniques
WO2006108047A2 (en) * 2005-04-05 2006-10-12 Biopure Corporation Oxygenated polymerized hemoglobin solutions and their uses for tissue visualization
US7410634B2 (en) * 2005-10-17 2008-08-12 Rockland Technimed Ltd. Tissue metabolic stress monitoring
AU2007314614A1 (en) * 2006-04-14 2008-05-08 Celsense, Inc. Methods for assessing cell labeling
EP2010646A2 (de) * 2006-04-14 2009-01-07 Carnegie Mellon University Zellbeschriftung und -quantifizierung für nukleare magnetresonanzverfahren
JP5645658B2 (ja) * 2007-07-10 2014-12-24 カーネギー メロン ユニバーシティー 核磁気共鳴技術のための細胞標識を製造するための組成物及び方法
AU2009241762B2 (en) * 2008-05-02 2015-07-16 Celsense Inc. Compositions and methods for producing emulsions for nuclear magnetic resonance techniques and other applications
WO2013043236A1 (en) * 2011-09-22 2013-03-28 Rockland Technimed, Ltd. Compositions and methods useful for realtime in situ physiological molecular imaging of oxygen metabolism

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775522A (en) * 1983-03-04 1988-10-04 Children's Hospital Research Foundation, A Division Of Children's Hospital Medical Center NMR compositions for indirectly detecting a dissolved gas in an animal
US4586511A (en) * 1983-03-04 1986-05-06 Children's Hospital Medical Center Methods and compositions for detecting and imaging a gas in an animal by nuclear magnetic resonance
DE3785054T2 (de) * 1986-01-24 1993-07-08 Childrens Hosp Medical Center Stabile emulsionen von stark fluorierten, organischen verbindungen.

Also Published As

Publication number Publication date
EP0386199A1 (de) 1990-09-12
WO1990001953A1 (en) 1990-03-08
IL91368A (en) 1995-05-26
EP0386199A4 (en) 1990-11-07
US4996041A (en) 1991-02-26
ATE121950T1 (de) 1995-05-15
AU4066589A (en) 1990-03-23
CA1336165C (en) 1995-07-04
IL91368A0 (en) 1990-04-29
JPH03500896A (ja) 1991-02-28
JP2655004B2 (ja) 1997-09-17
EP0386199B1 (de) 1995-05-03
DE68922485T2 (de) 1996-01-18

Similar Documents

Publication Publication Date Title
DE68922485D1 (de) Verfahren zur einführung von sauerstoff-17 in gewebe zur bildformung in einem magnetischen resonanzbildformungssystem.
Hunyadi et al. Keratinocyte grafting: a new means of transplantation for full-thickness wounds
Bergström et al. Comparison of the accumulation kinetics of L-(methyl-11C)-methionine and D-(methyl-11C)-methionine in brain tumors studied with positron emission tomography
MY109875A (en) Novel formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight surfactants.
Hopkins et al. Oxygen‐17 compounds as potential NMR T2 contrast agents: enrichment effects of H217O on protein solutions and living tissues
ATE92931T1 (de) Fluor- und phosphorhaltige amphiphilische molekuele mit oberflaechenaktiven eigenschaften.
Poirier-Quinot et al. High-resolution 1.5-Tesla magnetic resonance imaging for tissue-engineered constructs: a noninvasive tool to assess three-dimensional scaffold architecture and cell seeding
DE122005000008I1 (de) Kontrastmittel zur darstellun des Leber-Gallensystems mittels NMR-Kontrastmittel.
DE3872741T (de)
ES2181715T3 (es) Composiciones y procedimientos para la determinacion de estructuras de proteinas.
DE69332688D1 (de) Verwendung von modifiziertem c-reaktiven protein zur herstellung eines medikaments zur behandlung von krebs
DE69325184D1 (de) Verfahren zur verbesserung der fettsättigung während der bilderzeugung mittels magnetischer resonanz
Mealey Turn-over of carrier-free zirconium-89 in man
ES2188632T3 (es) Metodo para la produccion de tgf-b.
DE69417397D1 (de) Lösung, die igf-1 enthält
DE69009758D1 (de) Mittel für magnetische resonanzbilderzeugung.
Susi Keratinization in the mucosa of the ventral surface of the chicken tongue.
DJ et al. Hyaluronidase-sensitive acid mucopolysaccharides in liposarcomas.
Darby et al. Renin gene expression in vessels of the ovine renal cortex
Vorne et al. Comparison of 123I monoclonal granulocyte antibody and 99Tcm-HMPAO-labelled leucocytes in the detection of inflammation
Nakamura et al. Differences of Ca2+ regulation in skin fibroblasts from blacks and whites
PAPATHEOFANIS et al. Short-term effect of exposure to intense magnetic fields on hematologic indices of bone metabolism
DE69008762D1 (de) Retinsäureester von l-Cladinos, Verfahren zu deren Herstellung und ihre Verwendung in der Human- oder Veterinärmedizin und in der Kosmetik.
ATE37873T1 (de) Verfahren zur herstellung optisch aktiver 1,4dihydropyridine.
ATE89563T1 (de) Oxiran-pseudooligosaccharide, verfahren zu deren herstellung, deren verwendung und pharmazeutische praeparate.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee
8370 Indication related to discontinuation of the patent is to be deleted